Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.
作者信息
Guha Avirup, Derbala Mohamed H, Zhao Qiuhong, Wiczer Tracy E, Woyach Jennifer A, Byrd John C, Awan Farrukh T, Addison Daniel
出版信息
J Am Coll Cardiol. 2018 Aug 7;72(6):697-698. doi: 10.1016/j.jacc.2018.06.002.
Abstract
摘要
相似文献
1
Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.用于治疗淋巴系统恶性肿瘤的依鲁替尼起始治疗后出现的室性心律失常。
J Am Coll Cardiol. 2018 Aug 7;72(6):697-698. doi: 10.1016/j.jacc.2018.06.002.
2
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.使用依鲁替尼引发心房颤动的风险：一项系统评价与荟萃分析。
Blood. 2016 Jul 7;128(1):138-40. doi: 10.1182/blood-2016-05-712828. Epub 2016 May 31.
3
Management of adverse effects/toxicity of ibrutinib.伊布替尼的不良反应/毒性的管理。
Crit Rev Oncol Hematol. 2019 Apr;136:56-63. doi: 10.1016/j.critrevonc.2019.02.001. Epub 2019 Feb 10.
4
Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.因使用依鲁替尼治疗慢性淋巴细胞白血病导致的严重关节炎综合征。
J Oncol Pharm Pract. 2019 Jun;25(4):1003-1005. doi: 10.1177/1078155218772327. Epub 2018 May 3.
5
Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.接受布鲁顿酪氨酸激酶抑制剂依鲁替尼治疗淋巴白血病患者的脂膜炎
JAMA Oncol. 2015 Aug;1(5):684-6. doi: 10.1001/jamaoncol.2015.0457.
6
Sudden ventricular fibrillation and death during ibrutinib therapy-A case report.在伊布替尼治疗期间发生心室颤动和死亡：一例报告。
Eur J Haematol. 2019 Oct;103(4):442-443. doi: 10.1111/ejh.13290. Epub 2019 Jul 22.
7
Ibrutinib-induced polyneuropathy: A case report.依鲁替尼诱发的多发性神经病：一例报告。
J Oncol Pharm Pract. 2020 Sep;26(6):1501-1504. doi: 10.1177/1078155220903357. Epub 2020 Feb 6.
8
Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.加拿大某中心接受依鲁替尼治疗的复发或难治性慢性淋巴细胞白血病患者的剂量及治疗结果描述性分析。
Curr Oncol. 2019 Oct;26(5):e610-e617. doi: 10.3747/co.26.4957. Epub 2019 Oct 1.
9
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.伊布替尼单药治疗 Waldenström 巨球蛋白血症的临床试验之外的应用：实践模式、毒性和结果。
Br J Haematol. 2020 Feb;188(3):394-403. doi: 10.1111/bjh.16168. Epub 2019 Aug 29.
10
Ibrutinib-associated T-cell pseudolymphoma.依鲁替尼相关的T细胞假性淋巴瘤
Clin Exp Dermatol. 2019 Oct;44(7):828-830. doi: 10.1111/ced.13907. Epub 2019 Jan 8.
引用本文的文献
1
Beyond Atrial Fibrillation and Heart Failure: Ibrutinib-induced Pericardial Effusion.超越心房颤动和心力衰竭：依鲁替尼诱发的心包积液
J Community Hosp Intern Med Perspect. 2025 Jul 3;15(4):81-87. doi: 10.55729/2000-9666.1509. eCollection 2025.
2
Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.澳大利亚和新西兰关于接受布鲁顿酪氨酸激酶抑制剂治疗的慢性淋巴细胞白血病患者心血管管理的共识声明。
Intern Med J. 2025 Sep;55(9):1556-1569. doi: 10.1111/imj.70159. Epub 2025 Jul 26.
3
Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy.小分子激酶抑制剂在癌症治疗中的心脏毒性
Exp Hematol Oncol. 2025 May 9;14(1):68. doi: 10.1186/s40164-025-00660-5.
4
A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network.阿卡拉布替尼与依鲁替尼治疗慢性淋巴细胞白血病相关心血管事件的比较分析：来自全球联合网络的见解
Pharmacol Res Perspect. 2025 Jun;13(3):e70113. doi: 10.1002/prp2.70113.
5
Artificial Intelligence to Enhance Precision Medicine in Cardio-Oncology: A Scientific Statement From the American Heart Association.人工智能助力心血管肿瘤精准医学：美国心脏协会科学声明
Circ Genom Precis Med. 2025 Apr;18(2):e000097. doi: 10.1161/HCG.0000000000000097. Epub 2025 Feb 24.
6
Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and Expert Panel Recommendations.癌症治疗期间的心血管问题：证据差距与专家小组建议
JACC CardioOncol. 2024 Nov 5;6(6):815-834. doi: 10.1016/j.jaccao.2024.06.005. eCollection 2024 Dec.
7
Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study.伊布替尼与化疗免疫疗法在慢性淋巴细胞白血病中的心脏毒性差异：一项基于人群的研究。
J Clin Med. 2024 Dec 9;13(23):7492. doi: 10.3390/jcm13237492.
8
Epidemiology, clinical characteristics and potential mechanism of ibrutinib-induced ventricular arrhythmias.依鲁替尼诱发室性心律失常的流行病学、临床特征及潜在机制
Front Pharmacol. 2024 Nov 19;15:1513913. doi: 10.3389/fphar.2024.1513913. eCollection 2024.
9
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL.2024年淋巴瘤研究基金会关于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤治疗选择与序贯治疗的共识建议。
Blood Adv. 2025 Mar 11;9(5):1213-1229. doi: 10.1182/bloodadvances.2024014474.
10
Mitigating ibrutinib-induced ventricular arrhythmia and cardiac dysfunction with metformin.用二甲双胍减轻依鲁替尼引起的室性心律失常和心脏功能障碍。
Cancer Innov. 2024 Nov 13;4(1):e151. doi: 10.1002/cai2.151. eCollection 2025 Feb.
本文引用的文献
1
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.接受依鲁替尼治疗的患者心房颤动的累积发病率、危险因素及管理
Blood Adv. 2017 Sep 8;1(20):1739-1748. doi: 10.1182/bloodadvances.2017009720. eCollection 2017 Sep 12.
2
Ventricular arrhythmias and sudden death in patients taking ibrutinib.服用依鲁替尼的患者发生室性心律失常和猝死
Blood. 2017 May 4;129(18):2581-2584. doi: 10.1182/blood-2016-10-742437. Epub 2017 Feb 21.
3
Incidence of Idiopathic Ventricular Arrhythmias: A Population-Based Study.特发性室性心律失常的发病率：一项基于人群的研究。
Circ Arrhythm Electrophysiol. 2017 Feb;10(2). doi: 10.1161/CIRCEP.116.004662.
4
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.伊布替尼治疗复发慢性淋巴细胞白血病的 BTK 靶点。
N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19.
Zotero 插件